InSite's AzaSite meets Phase III endpoint

ISV's AzaSite ( ISV-401) met the primary endpoint of clinical resolution rate compared to vehicle (p<0.03) in an international Phase III trial in 685 patients with acute bacterial conjunctivitis. Last...